Organicell Regenerative Medicine, Inc. (OCEL)

Overview

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that aims to offer innovative solutions in the realm of degenerative diseases and regenerative medicine. Originating from a background with a different name, Biotech Products Services and Research, Inc., the company transitioned to its current identity in June 2018. Organicell has set its foundation on the principles of developing biological therapeutics with a special focus on non-cellular products derived from perinatal sources. Established in 2011 and based in Fort Lauderdale, Florida, Organicell has forged strategic research and development agreements with significant institutions such as the Centers for Disease Control and Prevention (CDC) and Oklahoma State University to push the boundaries of its lead product candidate, Zofin, alongside exploring other potential therapeutic technologies.

Products and Services

• Zofin:

Zofin stands as Organicell's flagship acellular biologic therapeutic, currently navigating through Phase I/II clinical trials. Crafted from perinatal sources, Zofin's therapeutic explorations extend to a variety of ailments including COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The product’s versatility and potential efficacy against such diverse conditions underline Organicell’s commitment to regenerative medicine and its capabilities in addressing degenerative illnesses.

• Patient Pure X:

Alongside Zofin, Organicell offers Patient Pure X, a cutting-edge autologous blood-derived biologic technology. Distinguished for its unique approach, Patient Pure X is administered into the body to harness the power of exosomes in cellular reprogramming and tissue repair. This technology exemplifies Organicell's innovative strides in leveraging the body's intrinsic healing mechanisms to foster regeneration and recovery.